Skip to content
NYSE · SERVICES-EDUCATIONAL SERVICES · LARGE CAP

Covista Inc. CVSA

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.0B
▲ 9.3% YoY
$251.6M
▲ 6.1% YoY
$392.7M
▲ 36.6% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Covista delivers education to its students at multiple campuses and online through five accredited institutions: Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. It serves 100,000 students and is supported by an alumni network of 400,000. As of June 30, 2026, Covista had 10,680 employees, including 5,643 visiting professors. The Company presents three reportable segments: Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry; Walden, which offers degree and certificate programs including those in nursing, education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice; and Medical and Veterinary, which includes the operations of AUC, RUSM, and RUSVM and offers degree and certificate programs in the medical and veterinary postsecondary education industry. AUC is located in St. Maarten with a satellite campus in Preston, England, and has graduated over 9,000 physicians since its inception. RUSM is located in Barbados and has graduated over 17,000 physicians since its inception. RUSVM is located in St. Kitts and has graduated over 7,500 veterinarians since its inception. Covista was incorporated under the laws of the State of Delaware in August 1987.

Written from the business description in Covista Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 6 August 2026. Every sentence was checked against that document before publication.

Growth

USD 2.0B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.0 · Net income 0.3
1B2B
2008201120142017202020232025
Compound annual growth
+10.4%
+16.8%
+6.1%
+14.1%
+39.2%
+29.1%
−1.8%
+50.9%
+38.9%
+25.8%
+19.5%
+15.8%
+3.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.8% a year over the five years to FY2025 — but profit grew faster: net income at +29.1%, earnings per share at +38.9%.

The share count fell from 0.05B to 0.03B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

13 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 19.6% · Net 12.9%
50%100%150%
200820162025
ROE
FY2025 · ROE 17.5%
10%20%-2%-4%-6%
200820162025
Three returns, three denominators.

Each USD of equity produced 17 cents of profit this year.

Cash & shareholders

USD 239.7M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 392.7
150M300M
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 239.7
100M200MDividendsNet buybacks
2008201120142017202020232025

USD 239.7M in buybacks — 95% of the year's profit went back to shareholders.

Total assetsUSD 3.0B
EquityUSD 1.4B
CashUSD 406.3M
Gross debtUSD 662.9M
Net debtUSD 256.5M
Current ratio1.09×

Net debt stands at 18% of equity.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CVSA, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B2.01.81.61.51.40.90.91.01.01.21.11.91.92.00.40.31.91.5
Operating income $B0.40.30.20.20.10.10.10.20.20.10.20.20.20.20.20.50.40.2
EBITDA $B0.40.40.30.20.10.10.10.20.20.20.20.20.30.30.30.60.50.3
Income tax $B0.10.10.00.0−0.00.0−0.00.00.10.00.00.00.00.00.10.20.10.1
Net income $B0.30.20.10.10.30.1−0.10.10.00.1−0.00.10.10.10.10.30.30.2
Free cash flow $B0.40.30.20.2−0.00.20.10.10.20.20.20.10.20.10.20.30.30.2
EPS, diluted $7.046.183.392.056.431.36−1.581.600.541.91−0.052.142.071.652.094.683.872.28
Dividend / sh $◌◌◌◌◌◌◌0.000.000.180.360.360.340.340.300.240.200.16
Payout %———————009−72617163013556
ROE %17.516.99.76.322.35.4−6.36.52.17.5−0.29.09.17.810.325.726.617.9
Shares out B0.030.040.040.040.050.050.050.060.060.060.060.060.060.060.060.070.07◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 69 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. Two checks were skipped: the share count is not tagged before 2009. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Educational Services
Listed onNYSE
Incorporated inDelaware
Fiscal year endsJune 30
Data on record since2008

Share this section

Download image